138 related articles for article (PubMed ID: 24066762)
1. More on JC viremia in natalizumab-treated patients with multiple sclerosis.
Subramanyam M; Belachew S; Compton T
N Engl J Med; 2013 Sep; 369(13):1279-80. PubMed ID: 24066762
[No Abstract] [Full Text] [Related]
2. More on JC viremia in natalizumab-treated patients with multiple sclerosis.
Major EO; Frohman E; Douek D
N Engl J Med; 2013 Sep; 369(13):1280. PubMed ID: 24066761
[No Abstract] [Full Text] [Related]
3. JC viremia in natalizumab-treated patients with multiple sclerosis.
Major EO; Frohman E; Douek D
N Engl J Med; 2013 Jun; 368(23):2240-1. PubMed ID: 23738566
[No Abstract] [Full Text] [Related]
4. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
Rossi F; Newsome SD; Viscidi R
Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab treatment for multiple sclerosis.
Ferreira ML
Arq Neuropsiquiatr; 2014 Dec; 72(12):911-2. PubMed ID: 25517640
[No Abstract] [Full Text] [Related]
6. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.
van Rossum JA; Vennegoor A; Balk L; Uitdehaag BM; Polman CH; Killestein J
Mult Scler; 2014 Jan; 20(1):108-11. PubMed ID: 23828867
[TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
Pitarokoili K; Gold R
Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
[No Abstract] [Full Text] [Related]
8. JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.
Travasarou M; Marousi S; Papageorgiou E; Karageorgiou CE
Clin Neurol Neurosurg; 2013 Jun; 115(6):827-9. PubMed ID: 22920632
[No Abstract] [Full Text] [Related]
9. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
Serana F; Chiarini M; Sottini A; Bertoli D; Giustini V; Tessitore MV; Caimi L; Capra R; Imberti L
J Neuroimmunol; 2014 Dec; 277(1-2):6-12. PubMed ID: 25468273
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
Berger JR; Houff SA; Major EO
MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
[TBL] [Abstract][Full Text] [Related]
11. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
12. Cerebellar syndrome in a man treated with natalizumab: From the National Multiple Sclerosis Society Case Conference Proceedings.
Lapides DA; Batchala PP; Donahue JH; Lisak RP; Meltzer EI; Narayan RN; Nath A; Frohman TC; Costello K; Goldman MD; Zamvil SS; Frohman EM
Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e546. PubMed ID: 30882020
[No Abstract] [Full Text] [Related]
13. Anti-JC-virus antibody prevalence in a German MS cohort.
Warnke C; Dehmel T; Posevitz-Fejfár A; Chan A; Berthele A; Schmidt S; Haas J; Kronsbein HC; Seitz F; Tackenberg B; Mäurer M; Gerbershagen K; Limmroth V; Adams O; Hartung HP; Gold R; Hemmer B; Wiendl H; Kieseier BC
Mult Scler; 2012 Jul; 18(7):1054-5. PubMed ID: 22740609
[No Abstract] [Full Text] [Related]
14. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Baldwin KJ; Hogg JP
Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
[TBL] [Abstract][Full Text] [Related]
15. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
16. Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
Jeantin L; Shor N; Pallix-Guyot M; Roos-Weil D; Bellanger A; Le Garff-Tavernier M; Papeix C; Weiss N; Pourcher V
J Neurol; 2024 Feb; 271(2):729-732. PubMed ID: 37910249
[No Abstract] [Full Text] [Related]
17. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
Fragoso YD; Mendes MF; Arruda WO; Becker J; Brooks JB; Carvalho Mde J; Comini-Frota ER; Domingues RB; Ferreira ML; Finkelsztejn A; Gama PD; Gomes S; Gonçalves MV; Kaimen-Maciel DR; Morales Rde R; Muniz A; Ruocco HH; Salgado PR; Albuquerque LB; Gama RA; Georgeto S; Lopes J; Oliveira CL; Oliveira FT; Safanelli J; Saldanha PC; Satomi M
Arq Neuropsiquiatr; 2013 Oct; 71(10):780-2. PubMed ID: 24212514
[TBL] [Abstract][Full Text] [Related]
18. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Carruthers RL; Chitnis T; Healy BC
Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
[TBL] [Abstract][Full Text] [Related]
19. Low JC virus antibody index during natalizumab treatment less safe than assumed?
Killestein J; Wattjes MP
Mult Scler; 2015 Dec; 21(14):1753-4. PubMed ID: 26449744
[No Abstract] [Full Text] [Related]
20. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Cutter GR; Stüve O
Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
